-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

Benzinga·04/08/2025 11:39:02
Listen to the news
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $133 price target.